申请人:Euroceltique, S.A.
公开号:US05010081A1
公开(公告)日:1991-04-23
A 6-thioxanthine of formula I or a pharmaceutically acceptable salt thereof ##STR1## wherein R.sub.3 is a C.sub.2 to C.sub.6 alkyl group, a C.sub.3 to C.sub.7 cycloalkyl group or a C.sub.4 to C.sub.8 cycloalkylalkyl group and R.sub.8 is a C.sub.1 to C.sub.6 alkyl group, a C.sub.3 to C.sub.7 cycloalkyl group or a C.sub.4 to C.sub.8 cycloalkylalkyl group provided that when R.sub.3 is an ethyl, n-propyl or n-butyl group, R.sub.8 is a C.sub.3 to C.sub.6 alkyl, a C.sub.3 to C.sub.7 cycloalkyl group or a C.sub.4 to C.sub.8 cycloalkylalkyl group. These 3,8-disubstituted-6-thioxanthines have enhanced bronchodilator activity.
公式I中的6-硫氧黄嘌呤或其药学上可接受的盐,其中R.sub.3是C.sub.2到C.sub.6烷基,C.sub.3到C.sub.7环烷基或C.sub.4到C.sub.8环烷基烷基,R.sub.8是C.sub.1到C.sub.6烷基,C.sub.3到C.sub.7环烷基或C.sub.4到C.sub.8环烷基烷基,但当R.sub.3是乙基、正丙基或正丁基时,R.sub.8是C.sub.3到C.sub.6烷基,C.sub.3到C.sub.7环烷基或C.sub.4到C.sub.8环烷基烷基。这些3,8-二取代-6-硫氧黄嘌呤具有增强的支气管舒张作用。